Glaucoma drug lowers blood sugar in type 2

A drug used for decades to treat glaucoma could be “the archetype for a potential class of type 2 diabetes therapy,” Australian researchers write.

Methazolamide treatment significantly lowered HBA1C in type 2 diabetes compared with placebo, a randomised study of 76 patients at three Australian sites showed.

The proportion of patients in the methazolamide group with HBA1C of 6.5% or under rose from 8% to 33% after 24 weeks of treatment, but remained